JP7396682B2 - イタコン酸誘導体の組成物及び使用方法 - Google Patents

イタコン酸誘導体の組成物及び使用方法 Download PDF

Info

Publication number
JP7396682B2
JP7396682B2 JP2020572891A JP2020572891A JP7396682B2 JP 7396682 B2 JP7396682 B2 JP 7396682B2 JP 2020572891 A JP2020572891 A JP 2020572891A JP 2020572891 A JP2020572891 A JP 2020572891A JP 7396682 B2 JP7396682 B2 JP 7396682B2
Authority
JP
Japan
Prior art keywords
alkyl
disease
compound
formula
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020572891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529752A (ja
JP2021529752A5 (https=
JPWO2020006557A5 (https=
Inventor
アドニア パパサナスィウ
Original Assignee
エルゴン ファーマシューティカルズ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エルゴン ファーマシューティカルズ エルエルシー filed Critical エルゴン ファーマシューティカルズ エルエルシー
Publication of JP2021529752A publication Critical patent/JP2021529752A/ja
Publication of JP2021529752A5 publication Critical patent/JP2021529752A5/ja
Publication of JPWO2020006557A5 publication Critical patent/JPWO2020006557A5/ja
Application granted granted Critical
Publication of JP7396682B2 publication Critical patent/JP7396682B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/44—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020572891A 2018-06-29 2019-07-01 イタコン酸誘導体の組成物及び使用方法 Active JP7396682B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862763735P 2018-06-29 2018-06-29
US62/763,735 2018-06-29
PCT/US2019/040121 WO2020006557A1 (en) 2018-06-29 2019-07-01 Compositions and methods of using itaconic acid derivatives

Publications (4)

Publication Number Publication Date
JP2021529752A JP2021529752A (ja) 2021-11-04
JP2021529752A5 JP2021529752A5 (https=) 2022-06-21
JPWO2020006557A5 JPWO2020006557A5 (https=) 2022-06-21
JP7396682B2 true JP7396682B2 (ja) 2023-12-12

Family

ID=68985877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020572891A Active JP7396682B2 (ja) 2018-06-29 2019-07-01 イタコン酸誘導体の組成物及び使用方法

Country Status (5)

Country Link
US (1) US12060310B2 (https=)
EP (1) EP3813815B1 (https=)
JP (1) JP7396682B2 (https=)
ES (1) ES3063485T3 (https=)
WO (1) WO2020006557A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55795A (fr) 2019-04-30 2022-03-09 Sitryx Therapeutics Ltd Dérivés d'acide itaconique et leurs utilisations dans le traitement d'une maladie inflammatoire ou d'une maladie associée à une réponse immunitaire indésirable
EP4237404A1 (en) * 2020-10-29 2023-09-06 Sitryx Therapeutics Limited Novel compounds
EP4326247A1 (en) 2021-04-23 2024-02-28 Helmholtz-Zentrum für Infektionsforschung GmbH Citraconic acid and derivatives thereof for use as a medicament
CN119685257B (zh) * 2024-12-16 2026-02-27 华中科技大学同济医学院附属协和医院 体外诱导t细胞免疫记忆分化的方法及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4467801B2 (ja) 1998-10-27 2010-05-26 サントリーホールディングス株式会社 解糖系代謝調節剤の製造法
WO2011035332A1 (en) 2009-09-21 2011-03-24 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r ( chemr23 ) modulators
JP2015504863A (ja) 2011-12-12 2015-02-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピペリジニルナフチル酢酸
US20150086986A1 (en) 2011-09-23 2015-03-26 Universite Du Luxembourg Method to predict the presence of inflammation or itaconic acid, irg1 and/or protein irg1 in a subject and pharmaceutical composition for treating or preventing inflammation
JP2015516965A (ja) 2012-04-03 2015-06-18 アポセンス リミテッドＡｐｏｓｅｎｓｅ Ｌｔｄ． 診断指標及び治療指標のための新規な標的指向性薬剤
WO2017142855A1 (en) 2016-02-15 2017-08-24 Artyomov Maxim Immunomodulatory agents and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260479A (en) * 1991-12-16 1993-11-09 Merck & Co., Inc. Inhibitors of farnesyl protein transferase

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4467801B2 (ja) 1998-10-27 2010-05-26 サントリーホールディングス株式会社 解糖系代謝調節剤の製造法
WO2011035332A1 (en) 2009-09-21 2011-03-24 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r ( chemr23 ) modulators
US20150086986A1 (en) 2011-09-23 2015-03-26 Universite Du Luxembourg Method to predict the presence of inflammation or itaconic acid, irg1 and/or protein irg1 in a subject and pharmaceutical composition for treating or preventing inflammation
JP2015504863A (ja) 2011-12-12 2015-02-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピペリジニルナフチル酢酸
JP2015516965A (ja) 2012-04-03 2015-06-18 アポセンス リミテッドＡｐｏｓｅｎｓｅ Ｌｔｄ． 診断指標及び治療指標のための新規な標的指向性薬剤
WO2017142855A1 (en) 2016-02-15 2017-08-24 Artyomov Maxim Immunomodulatory agents and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bagavant, G.; Gole, S.R.; Joshi, V.W.; Soni, S.B.，"Studies on anti-inflammatory and analgesic activities of itaconic acid systems. Part 1: Itaconic acids and diesters"，Indian Journal of Pharmaceutical Sciences，1994年，Vol. 56, No. 3，pp. 80-85
Mizufune, Hideya; Nakamura, Minoru; Mitsudera, Hiroyuki，"Process research on arylnaphthalene lignan aza-analogues: a new palladium-catalyzed benzannulation of α,β-bisbenzylidenesuccinic acid derivatives"，Tetrahedron，2006年，Vol. 62, No. 36，pp. 8539-8549

Also Published As

Publication number Publication date
ES3063485T3 (en) 2026-04-16
JP2021529752A (ja) 2021-11-04
EP3813815A1 (en) 2021-05-05
EP3813815C0 (en) 2026-01-28
EP3813815A4 (en) 2022-04-20
US20210261495A1 (en) 2021-08-26
EP3813815B1 (en) 2026-01-28
US12060310B2 (en) 2024-08-13
WO2020006557A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
JP7396682B2 (ja) イタコン酸誘導体の組成物及び使用方法
AU2022297504B2 (en) Protein inhibitor or degrading agent, pharmaceutical composition containing same and pharmaceutical use
JP5512665B2 (ja) トリアゾロピリジンｊａｋ阻害剤化合物と方法
US11613542B2 (en) Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
JP6632746B2 (ja) 癌を治療するための１−テトラヒドロピラニルカルボニル−２，３−ジヒドロ−１ｈ−インドール化合物
JP7324196B2 (ja) 統合的ストレス経路の調節剤
AU2020368368B2 (en) Broad spectrum anti-cancer compounds
CN111247142B (zh) 作为jak激酶抑制剂的嘧啶化合物
JP2021502364A (ja) 新規なスルホンアミドカルボキサミド化合物
JP2021501780A (ja) 統合的ストレス経路の調節剤
JP2011525193A (ja) トリアゾロピリジンｊａｋ阻害剤化合物と方法
JP2023508097A (ja) タンパク質分解剤化合物の製造方法及び使用
EP2379561A2 (en) Mlk inhibitors and methods of use
CN113301962A (zh) 用于治疗癌症的杂环nlrp3调节剂
WO2016207212A1 (en) Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway
CA3068083A1 (en) Indole-formamide derivative, preparation method therefor and use thereof in medicine
CN113301963A (zh) 用于治疗癌症的作为nlrp3调节剂的取代的喹唑啉类
EP3774843B1 (en) Dipeptide piperidine derivatives
ES3055177T3 (en) Condensed pyridazine or pyrimidine as btk inhibitors
US11827597B2 (en) Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
JP2022529855A (ja) グリセロ－マンノ－ヘプトースホスフェートの誘導体および免疫応答をモジュレートする際のそれらの使用
US9567306B2 (en) Inhibition of macrophage migration inhibitory factor in melanoma and colon cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220613

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230928

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231122

R150 Certificate of patent or registration of utility model

Ref document number: 7396682

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150